Executive Director
New York Office | kylor.hua@torreya.com | 212.257.5817
Kylor Hua, an Executive Director at Torreya, advises clients on strategic transactions in the US and Asia.
He joined Torreya in 2013, having previously worked as a summer analyst at the firm.
Kylor received a B.A., magna cum laude from the University of Rochester. He holds double majors in economics and business strategy, and brain and cognitive science, and a minor in Japanese. He is fluent in Mandarin and Japanese.
|
Acquisition of |
![]() |
$225 million
September 2020
|
![]() |
Acquisition of generics business of |
![]() |
$1.05 billion
June 2017
|
![]() |
Sale of Intrathecal business to |
![]() |
$203 million
March 2017
|
![]() |
Company sale to |
![]() |
$100+ million
December 2015
|
![]() |
Acquisition of Donnatal® from |
![]() |
$328 million
May 2014
|
![]() |
Co-advisor on direct public offering |
![]() |
$15 million
August 2020
|
![]() |
Strategic investment from |
![]() |
$30 million
February 2020
|
![]() |
Divestiture of China right of Sai Bo Song™ (buprenorphine, naloxone) tablet to |
![]() |
Up to $122.5 million
February 2019
|
![]() |
JV Partnership in China with |
![]() |
$50 million
December 2018
|
![]() |
Sale of Sevelamer ANDA to |
![]() |
Undisclosed
October 2018
|
![]() |
Debt recapitalization and acquisition of NextWave Pharmaceuticals from |
![]() |
$125 million
September 2018
|
![]() |
License of AJT-240 in hemodialysis in China to |
![]() |
Up to $24 million
June 2018
|
![]() |
Sale of consumer products to |
![]() |
Undisclosed
February 2018
|
![]() |
Sale of ANDA portfolio to |
![]() |
Undisclosed
January 2018
|
![]() |
Sale to |
![]() |
Up to $34 million
November 2017
|
![]() |
Sale of generics portfolio to |
![]() |
$18 million
August 2017
|
![]() |
Sale of company to |
![]() |
Undisclosed
June 2017
|
![]() |
Merger with |
![]() |
$251 million
December 2016
|
![]() |
Collaboration agreement for Emricasan with |
![]() |
$50 million upfront
December 2016
|
![]() |
Sale of ANDA portfolio to |
![]() |
Undisclosed
October 2016
|
![]() |
Sale of abbreviated new drug applications |
![]() |
Undisclosed
February 2016
|
![]() |
Sale of assets to |
![]() |
$10 million
February 2016
|
![]() |
Acquisition of |
![]() |
CAD $47 million
October 2015
|
![]() |
License of global rights for Anti-TGF-beta antibody program to |
![]() |
Up to $517 million
October 2015
|
![]() |
Sale of abbreviated new drug application portfolio to |
![]() |
$25 million +
profit share July 2015
|
![]() |
Sale of Zonalon® to |
![]() |
Undisclosed
March 2015
|
![]() |
Divestiture of certain abbreviated new drug applications to |
![]() |
Up to $18 million
October 2014
|